[ | E-mail ] Contact: Joe Dangornewsbureau@mayo.edu 507-284-5005Mayo Clinic CHICAGO Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were…
Source:Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Sunday, June 1, 2014
Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment